Caribou Biosciences, Inc. - CRBU STOCK NEWS

Caribou Biosciences (Nasdaq: CRBU) announced that the FDA granted Fast Track designations to two of its therapies: CB-010 for refractory systemic lupus erythematosus (SLE) and CB-012 for relapsed or refractory acute myeloid leukemia (r/r AML). CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial for lupus nephritis and extrarenal lupus, set to begin by year-end 2024. CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, is currently being evaluated in the ongoing AMpLify Phase 1 clinical trial for r/r AML. These designations highlight the significant unmet medical needs and the potential of Caribou's off-the-shelf CAR-T cell therapies.

Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024, and the 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024.

During these events, Caribou's leadership team will engage in one-on-one meetings with registered investors. This presents an opportunity for the company to showcase its progress and discuss its innovative CRISPR genome-editing technology with potential investors. For those interested in more details about Caribou's participation, additional information can be found on the Events page of the company's website.

Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer. With 15 years of experience in clinical drug development of cellular therapies and biologics, Dr. Albertson will lead the company's clinical, regulatory, and medical affairs functions. She will oversee four clinical programs focusing on hematologic malignancies and autoimmune diseases.

Dr. Albertson's background includes roles at Lyell Immunopharma, where she initiated two Phase 1 trials for CAR-T cell and TIL therapies, and at Juno Therapeutics, where she led the development of BREYANZI, an FDA-approved therapy for large B cell lymphoma. Her expertise in strategic clinical development of CAR-T cell therapies is expected to be valuable as Caribou advances its allogeneic CAR-T cell therapies.

Caribou Biosciences (Nasdaq: CRBU) reported Q2 2024 financial results and provided a business update. The company is advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases, with data reports planned for 2024 and H1 2025. Key highlights include:

- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients in the CB-010 ANTLER Phase 1 trial
- $311.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into H2 2026
- Presented promising CB-010 clinical data at ASCO 2024, showing potential to rival autologous CAR-T therapies
- Advancing CB-011 for multiple myeloma and CB-012 for acute myeloid leukemia
- Planning to initiate CB-010 GALLOP Phase 1 trial for lupus by year-end 2024

Financial results show $3.5 million in licensing and collaboration revenue, $35.5 million in R&D expenses, and a net loss of $37.7 million for Q2 2024.

Caribou Biosciences (Nasdaq: CRBU) has appointed Dr. Terri Laufer to its scientific advisory board. Dr. Laufer is an immunologist and rheumatologist with over 35 years of experience in autoimmune disease research. She is an emeritus associate professor at the Perelman School of Medicine and practices at Penn Presbyterian Medical Center and Philadelphia VA Medical Center. Her expertise will support Caribou's GALLOP clinical program, which evaluates CB-010 for lupus. Dr. Laufer's research focuses on T cell development and MHC/HLA class II-positive antigen-presenting cells. She holds degrees from Princeton and Columbia University and completed postdoctoral research at Harvard.

Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety and efficacy. The trial results indicated a median progression-free survival (PFS) of 14.4 months in patients with ≥4 HLA matches, compared to 2.8 months for those with ≤3 matches. CB-010 was well tolerated with no Grade 3 or higher cytokine release syndrome or graft-versus-host disease observed. Caribou plans to enroll ~20 additional patients to confirm these findings, with initial data expected in H1 2025. A pivotal Phase 3 trial is anticipated to start in H2 2025, pending confirmation of improved outcomes.

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing company, announced its upcoming participation in key events. On June 2, 2024, the company will host a webcast at 7:00 pm CDT, discussing CB-010 ANTLER Phase 1 trial data in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) from the 2024 ASCO Annual Meeting. The presentation will include insights from notable figures in hematology and oncology. Additionally, Caribou will present at the Jefferies Global Healthcare Conference on June 5, 2024, and participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. Webcasts for these events will be available on the Caribou website for 30 days.

Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.

Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.